\u0160odien, 30. apr\u012bl\u012b akciju sabiedr\u012bba Grindeks \u201eNasdaq Riga\u201d iesniegusi 2019. gada revid\u0113tos konsolid\u0113tos finan\u0161u p\u0101rskatus un Nefinan\u0161u zi\u0146ojumu. Revid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, ir sasniegusi 13,4 milj. eiro. Koncerna apgroz\u012bjums 2019. gad\u0101 bija 141,4 milj. eiro. 2019. gad\u0101 Koncerna sara\u017eot\u0101 produkcija tika eksport\u0113ta uz 84 pasaules valst\u012bm kopum\u0101 par 132,0 milj. eiro.<\/p>\n\n\n\n
Nefinan\u0161u zi\u0146ojums sagatavots atbilsto\u0161i Finan\u0161u instrumentu tirgus likuma 56.3 pantam, vadoties p\u0113c Eiropas Komisijas pamatnost\u0101dn\u0113m par nefinansi\u0101las inform\u0101cijas snieg\u0161anu.<\/p>\n\n\n\n
AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Dr. chem. Juris Hme\u013c\u0146ickis: \u201e2019. gads ir sekm\u012bgi nosl\u0113dzies, sasniedzot 13,4 milj. eiro pe\u013c\u0146u, kas ir garants t\u0101l\u0101kai koncerna att\u012bst\u012bbai. P\u0113d\u0113jos gados farm\u0101cijas biznesa vide main\u0101s, un farm\u0101cijas industrija darbojas apst\u0101k\u013cos, kuros klientu vajadz\u012bbas k\u013c\u016bst aizvien specifisk\u0101kas. Grindeks koncerna potenci\u0101ls sniegt pacientu vajadz\u012bb\u0101m piem\u0113rotus risin\u0101jumus ir \u013coti augsts. M\u016bsu strat\u0113\u0123iskais biznesa att\u012bst\u012bbas m\u0113r\u0137is \u2013 b\u016bt soli priek\u0161\u0101 spraigajai farm\u0101cijas industrijas konkurencei un izv\u0113rst savu darb\u012bbu gan m\u016bsu tradicion\u0101lajos tirgos, gan Eiropas Savien\u012bb\u0101, Dienvidaustrum\u0101zijas valst\u012bs un ASV.\u201d<\/em><\/p>\n\n\n\n Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2019. gad\u0101 bija 132,2 milj. eiro. P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2019. gad\u0101 veidoja 77,9 milj. eiro. Sal\u012bdzinot ar 2018. gadu, 2019. gad\u0101 noz\u012bm\u012bgs p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Baltkrievij\u0101 par 20%, Gruzij\u0101 par 18%, Moldov\u0101 par 13% un Arm\u0113nij\u0101 par 12%. Gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms Eiropas Savien\u012bbas valst\u012bs 2019. gad\u0101 sasniedza 50,2 milj. eiro. P\u0101rdo\u0161anas apjoms 2019. gad\u0101, sal\u012bdzinot ar 2018. gadu, Francij\u0101 ir palielin\u0101jies 3 reizes, Zviedrij\u0101 un \u010cehij\u0101 2 reizes, Ung\u0101rij\u0101 par 52%, bet Lielbrit\u0101nij\u0101 par 46%.<\/p>\n\n\n\n 2019. gad\u0101 akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 8,6 milj. eiro. Liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tika veikts uz ES valst\u012bm, Jap\u0101nu, Austr\u0101liju un Kan\u0101du. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2019. gad\u0101 bija deksmedetomid\u012bns, ksilaz\u012bns un pimobend\u0101ns.<\/p>\n","protected":false},"excerpt":{"rendered":" \u0160odien, 30. apr\u012bl\u012b akciju sabiedr\u012bba Grindeks \u201eNasdaq Riga\u201d iesniegusi 2019. gada revid\u0113tos konsolid\u0113tos finan\u0161u p\u0101rskatus un Nefinan\u0161u zi\u0146ojumu. Revid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna…<\/p>\n","protected":false},"author":3,"featured_media":3075,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3078","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=3078"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3078\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/3075"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=3078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=3078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=3078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}